Synthesizing small proteins and long synthetic peptides using traditional solid-phase peptide synthesis (SPPS) can present several challenges and is often an expensive endeavor. To overcome the typical obstacles, AmideBio has developed a novel recombinant-chemical hybrid strategy, the patented BioPureTM process, which is scalable and ideally suited for the manufacturing of difficult, hydrophobic, toxic, and amyloidogenic peptides, no matter the polypeptide length. As a result, AmideBio peptides are extremely economical, while still delivering the validated high-purity that you require.
AmideBio has constructed a proprietary set of expression vectors that achieve high yields of target peptides and fusion proteins. The expressed target is easily isolated from lysed cells using conventional chromatography followed by low-cost proprietary cleavage methods that release highly pure target product.
New England Peptide | Peptides International is proud to introduce a line of AmideBio products that complement our current product lines by allowing us to provide high-quality, longer peptides.
Located in Boulder, Colorado, AmideBio is a preclinical stage biotech company pursuing a series of therapeutic targets and diagnostics in the diabetes related metabolic disease space. The company continues to use their proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides for the research community in the pursuit of novel treatments for a variety of diseases.
Please visit our dedicated webpage of all the AmideBio products that New England Peptide | Peptides International offers.